Long-Term Follow-Up of Subjects in Gene Transfer Clinical Protocols Vector Classes with Potential for Long-Term Risks Carolyn A. Wilson, Ph.D. Division.

Slides:



Advertisements
Similar presentations
Gene Therapy.
Advertisements

Replacement of Defective Genes A story of familial hypercholesterolemia By, Russell Brown, Amber Ellis, and Stacey Leonard.
Option F: Microbes and Biotechnology F.3 Microbes and Biotechnology.
Chapter 19 Lecture Concepts of Genetics Tenth Edition Cancer and Regulation of the Cell Cycle.
F3 Microbes and biotechnology
Molecular Biology. It’s a Matter of Perspective The investigators who submit IBC protocols want to perform their experiments safely. The investigators.
Chapter 16 Human Heredity by Michael Cummings ©2006 Brooks/Cole-Thomson Learning Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified)
Copyright (c) by W. H. Freeman and Company Chapter 24 Cancer.
Cancer Gene Therapy …Using Tumor Suppressor Genes.
Biotechnological techniques
Gene therapy progress and prospects cancer. Gene Therapy Primary challenge for gene therapy – Successfully delivery an efficacious dose of a therapeutic.
Please write your field of dissertation on the blank sheet.
Biosafety and recombinant DNA technology. Involves.... Experiments involving the construction or use of GMOs should be conducted after performing a biosafety.
Retroviral Insertional Mutagenesis and Cancer in Animal Models
KEY CONCEPT Genetics provides a basis for new medical treatments.
Recombinant DNA Technology Site directed mutagenesis Genetics vs. Reverse Genetics Gene expression in bacteria and viruses Gene expression in yeast Genetic.
NOTES: CH 18 part 2 - The Molecular Biology of Cancer
Food and Drug Administration Food and Drug Administration Center for Biologics Evaluation and Research Biological Response Modifiers Advisory Committee.
Genome Structure of Retroviruses
Fundamentals of Biotechnology
Gene therapy Fabrizia Urbinati 01/12/2010.
Gene Therapy. What is Gene Therapy? Defective genes make non-functional proteins, creating genetic disorders Gene therapy corrects defective genes by.
Chapter 4 Cellular Oncogenes ~ Mar 22, 2007.
What must DNA do? 1.Replicate to be passed on to the next generation 2.Store information 3.Undergo mutations to provide genetic diversity.
Cancer &Oncogenes. Objectives Define the terms oncogene, proto-oncogenes and growth factors giving examples. Describe the mechanisms of activations of.
Gene Therapy AP Biology Unit 2 + What is Gene Therapy? A way to treat or cure diseases by inserting the “correct” DNA into the cell. Most promising for.
GENE THERAPY. What is gene therapy? Gene therapy is the introduction of normal genes into cells that contain defective genes.
DNA Chips Attach DNA to tiny spots on glass slides (i.e., chip). Hybridize fluorescently-labeled DNA probes to chip. Detect hybridization to different.
23.1 Cancer Is a Group of Diseases Characterized by Cell Proliferation.
Viral Vector and Non-viral Vector. Viral Life cycle Infection Phase Replication Phase.
GENE THERAPY.
Gene Therapy By: Chris Smith and Darran Prewitt. What is gene therapy? Why is it used? Gene therapy = Introduction of normal genes into cells that contain.
Recombinant DNA What is the basis of recombinant DNA technology? How does one “clone” a gene? How are genetically modified organisms (GMOs) created? Illustration.
“Because clinical experience is still so limited, it is not possible to exclude longterm adverse effects of gene transfer therapy, such as might arise.
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Copyright © 2002 Pearson Education, Inc., publishing as Benjamin Cummings Section D: The.
Section S Tumor viruses and oncogenes
Lecture 28 Genetics of Cancer Copyright © 2010 Pearson Education Inc.
Gene Transfer. Comparison of different viral vectors Viral vectortitersmanupilation of immunogenicityinfecting of tropism non-dividing cells Adenovirus10.
Chapters 15 – 17 Regulation of Gene Expression Development, Stem Cells, and Cancer Viruses.
BIOLOGY CONCEPTS & CONNECTIONS Fourth Edition Copyright © 2003 Pearson Education, Inc. publishing as Benjamin Cummings Neil A. Campbell Jane B. Reece Lawrence.
Histone protein modification I- Histone acetylation /deacetylation II- Histone phosphrylation/dephosphrylation.
GENETICS AND GENETICALLY LINKED DISEASES Chapter 22.
Gene Therapy (I) “Introduction to Gene Therapy”
Have a positive role in cell division Have a negative role in cell division Have a role in the maintenance of DNA integrity Genes altered in cancer typically:
© 2012 Pearson Education, Inc. Lecture by Edward J. Zalisko PowerPoint Lectures for Campbell Biology: Concepts & Connections, Seventh Edition Reece, Taylor,
In most gene therapy studies, a "normal" gene is inserted into the genome to replace an "abnormal," disease-causing gene. A carrier molecule called a.
Gene Therapy (II) “Viral Gene Transfer Methods” Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
The Biology of Cancer Second Edition CHAPTER 4 Cellular Oncogenes
Gene Therapy Mostafa A. Askar NCRRT By M.Sc. In Molecular Biology
Georgetown UNIVERSITY Overview of Gene Transfer as an Evolving Neurotherapeutic Modality Howard J Federoff, MD, PhD Georgetown University Medical Center.
THE GENETIC BASIS OF CANCER
CANCER.
Cancer as a genetic disease
Concept 18.5: Cancer results from genetic changes that affect cell cycle control The gene regulation systems that go wrong during cancer are the very same.
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
Genetics of Cancer.
Relationship between Genotype and Phenotype
KEY CONCEPT Genetics provides a basis for new medical treatments.
Genes The basic unit of heredity Encode how to make a protein
Relationship between Genotype and Phenotype
Recombinant DNA Technology
Gene Therapy Learning Goal: To explore gene therapy. Success Criteria:
KEY CONCEPT Genetics provides a basis for new medical treatments.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Gene Therapy Section 6.5.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Cancer Modeling in the Modern Era
KEY CONCEPT Genetics provides a basis for new medical treatments.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Presentation transcript:

Long-Term Follow-Up of Subjects in Gene Transfer Clinical Protocols Vector Classes with Potential for Long-Term Risks Carolyn A. Wilson, Ph.D. Division of Cellular and Gene Therapies CBER, FDA

Overview Scientific basis for long-term risks of gene transfer –long-term patient follow-up –short-term patient follow-up Properties of gene transfer vectors Gene transfer vectors and methods that share these properties

Properties of Gene Transfer Vectors with Potential for Long-term Risks Integration into host genomic DNA in somatic cells Integration into host genomic DNA in germ cells Contamination with replication-competent virus (integrating viruses)

Integration into Host Genomic DNA in Somatic Cells: Biological Effects Expression of the transgene product Chromosomal rearrangement, e.g., translocations Activation of gene expression via strong viral promoter or enhancer (up to 100 kbp distally) Disruption of transcriptional or translational control regions Dysregulated gene expression

What Is the Likelihood that Gene Transfer Vector Integration Would be Tumorigenic? ~80,000 genes (3-5% of genome is coding or transcriptional control regions) ~130 loci identified as “oncogenes” or proto- oncogenes (0.16% of total)* Tumor formation is typically multi-step process Insertional mutagenesis being potentially the first *The Cancer Genome Anatomy Project, Tumor Suppressor and Oncogene Directory

Rationale for Long-term Follow-up to Identify Risk of Vector DNA Integration Studies with murine retroviruses demonstrate –High level of virus replication is required for tumorigenesis –Multiple steps are involved in tumorigenesis past provirus insertion –Long latencies prior to tumor formation Data suggest risk of tumorigenesis from gene transfer vector integration is low, effects are long-term

Long-term follow-up -- Unresolved issues Gene transfer vectors –range of integration frequencies –variable integration frequencies What properties trigger the need for long-term follow-up? –Characteristics of gene transfer method? –Minimum frequency of integration events?

Properties of Gene Transfer Vectors with Potential for Long-term Risks Integration into host genomic DNA in somatic cells Integration into host genomic DNA in germ cells –Effects are long-term –Patient follow-up is typically short-term Contamination with replication-competent virus

Integration into host genomic DNA in germ cells: Risks Biological Effects: –None –Genetic disorders –Birth defects –Lethality to developing fetus Societal Issues: –Deliberate germ line alteration deemed unacceptable –Unknown public acceptance of inadvertent germ line alteration

What Is the Likelihood that Gene Transfer Vector Integration in Germ Cell DNA Would Be Deleterious? Zebrafish and Mice –Retroviruses used as insertional mutagens to study development: Effects require homozygosity Transposable Elements in the Human Genome* –33 retrotransposition events identified result in human disease (hemophilia A and B, ß-thalassemia, muscular dystrophy) –Background rate of retrotransposition: 1/ germ cells *Kazazian, H., Science 289:1152, 2000

Potential for Integration into Genome of Germ Cells Highly dependent upon route of administration –Ex vivo gene transfer, little to no risk –Localized injections, low risk –Localized injections to gonadal regions, risk –Systemic injections, risk

Potential for Integration into Genome of Germ Cells Localized injections to gonadal regions –Sato, M., et al, 1999, Sperm-mediated gene transfer by direct injection of foreign DNA into mouse testis. Transgenics 2:357 Systemic injections –Reaves, P.Y., et al, 1999, Permanent cardiovascular protection from hypertension by the AT1 receptor antisense gene therapy in hypertensive rat offspring. Circulation Research 85:e44-e50.

Summary Factors influencing long-term risks –Integration of gene transfer vector –Dose of gene transfer vector –Presence of replicating integrating virus –Route of administration (for germ cell integration) –Immune status of recipient Long-term adverse events predicted –Malignancies (somatic cell integration) –Genetic disorders, birth defects, embryonic lethalities (germ cell integration)

Will long-term follow-up of patients provide scientific data to assess the long-term risks of gene transfer research? If so, how can this best be achieved?